Welcome to Evermed
In Pursuit of Better Health Solution.
Fast Growing Pharma Company
While the pharmaceutical industry might be
regarded as the ultimate defensive sector – the need
to preserve and enhance human health is, after all,
an inexorable imperative – it is not immune to the
ebb and flow of global market cycles.
Evermed is ranks the UK’s fastest-growing, privately-owned pharmaceutical businesses according to their revenue growth over the past two years (the businesses must have reported revenues of more than £1m in the first year of assessment to be included).
Founder, CEO of evermed
“The company was launched on the premise that there was a real sea change taking place in the pharma industry, with the senior leaders of businesses waking up to the value of their data.”
Success requires talent with both of the technological expertise – particularly in fields such as data analytics and artificial intelligence – and pharma sector knowledge.
Harnessing their specialist experience and expertise – often earned over long careers in the sector – the entrepreneurial management teams running companies are delivering remarkable results.
The significant number of technology businesses are likely to increase in future rankings given the phenomenal rates of growth that innovative young companies are able to generate. The only question mark is how long some of these businesses will retain their independence
Specialists like Prescient Healthcare Group bring evidence-based design thinking and decision making to clinical and commercial strategy ensuring the scientific potential of a molecule is optimally translated into a value proposition that resonates with stakeholders as relevant, differentiated and meaningful.
Businesses such as Charnwood often operate very collaboratively, partnering with other preclinical CROs in adjacent disciplines so that clients have access to all the services they need from a collection of specialists rather than using a more generalist one-stop-shop.
The business’s success reflects its commitment to innovation. The Morningside team identifies niche molecules in a wide range of therapeutic areas, developing products which traditionally have been difficult to develop and enabling it to lead the market